Synergy research is a new approach to phytomedicinal research. Three events have promoted this development:
An analogous paradigm change in phytotherapy is not necessary because phytotherapy from its very beginning used primarily multidrug combinations. Practitioners have observed in their long-term application of herbal preparations that, in many cases, these showed a better efficacy than isolated single constituents thereof, and explained this as synergistic effects caused through the acting together of single active principles of a phytopreparation.
A first approach towards rationalizing this synergy effect was made by Berenbaum [1] . He developed, with the isobol method, a pharmacological tool to differentiate between real synergy and additional effects of a mixture of two plant constituents or extracts. He defined a synergy effect of a drug combination as an effect greater than what would be expected from the sum of the effects of the single components. With this method, we were able to confirm this synergistic effect for a mixture of ginkgolide A and B using an in vitro, PAF-induced thrombocyte aggregation model [2] . Meanwhile, many other in vitro and also in vivo examples of proven synergy effects have been described in two review articles [3, 4] . Pharmacological evidence for synergy effects has been documented for monoextracts such as Ginkgo biloba, Hypericum perforatum, Piper methysticum (Kava kava), Cannabis sativa, Valeriana officinalis, and Zingiber officinalis, along with many other herbal extracts.
Recently, interesting in vitro and in vivo synergy effects have been reported for combinations of extracts or single natural products with antibiotics which antagonize bacterial resistance against antibiotics [5] . One exciting example was reported for a combination of grapeseed (Vitis vinifera) with amphothericine ß, which strikingly enhanced the survival rate of mice infected with Candida albicans [6] . The various possible mechanisms of action underlying this antagonizing effect against bacterial resistance are described by Hemaiswarya et al. [5] . Until recently, the synergy effects underlying these pharmacological and therapeutic phenomena had no rational explanation. Preliminary investigations aided partially by classical and molecular-biological NPC Natural Product Communications 2009 Vol. 4 No. 2 303 -304 methods came to the conclusion that multitarget interactions with different enzymes, receptors signal transduction systems or genes could be primarily responsible for these synergy effects. Additionally, pharmacokinetic interactions additionally could be the cause of synergy effects, including the enhancement of the solubility of the main drug through another in the mixture and thereby the increased resorption and availability rate of the main component.
This mechanism could be confirmed if pure hypericin of Hypericum perforatum were combined with sufficient amounts of flavonoids and proanthocyanidins. Hypericin alone generated practically no antidepressant effect, as confirmed by the forced swim test of Porsolt. However, if the mentioned polyphenols were present in sufficient concentration, a significant antidepressant effect could be registered [7] . It can be suggested that this second mechanism of synergy interaction is added to the multitarget effect.
There is no question that existing synergy effects could be best confirmed through clinical trials if carried out in comparison with synthetic standard drugs using the correct indication and adequate dosages. Within the last 25 years, more than 200 comparative, double-blind, placebo-controlled trials have been performed using standardized mono-and multiextract combinations in comparison with synthetic drugs. These standardized phytopreparations show therapeutic equivalence to standard drugs with the additional advantage of fewer or no side-effects relative to chemosynthetics. These results are good evidence that synergistic effects are the cause of this therapeutic equivalence [8] .
In summarizing the results available so far, we can conclude that progress in synergy research will not only provide new legitimisation for phytotherapy, but also enhance the possibility to use new phytodrugs alone or in combination with chemotherapeutics for the treatment of diseases which have been treated previously through chemotherapy only.
